• Aluminium pouches with a Microwell Plate coated with antibody to human IL-1β (8x12)
• 2 vials human IL-1β Standard lyophilized, 500 pg/ml upon reconstitution
• 2 vials concentrated Biotin-Conjugate anti-human IL-1β antibody
• 2 vials Streptavidin-HRP solution
• 1 bottle Standard /sample Diluent
• 1 bottle Biotin-Conjugate antibody Diluent
• 1 bottle Streptavidin-HRP Diluent
• 1 bottle Wash Buffer Concentrate 20x (PBS with 1% Tween-20)
• 1 vial Substrate Solution
• 1 vial Stop Solution
• 4 pieces Adhesive Films
• package insert

Interleukin-1 (IL-1), originally described as lymphocyte activating factor (LAF) for its effects on thymocytes(1), is a polypeptide cytokine with two molecular forms. The two distinct molecular forms of IL-1 are thought to be derived from two genes(2,3). After transcription, as 31kD precursor polypeptide is cleaved to give rise to mostly cell membrane associated IL-1? and secreted IL-1?. Both have the same molecular weight of 15kD but have different isoelectric points of 5 and 7, respectively.

Despite sequence homology of only 20%, both forms are thought to bind to the same receptor(4). IL-1 inhibitors that vary only in their degree of glycosylation have been described to bind to the IL-1 receptor(5). These inhibitors are structurally related to IL-1β and may be important in regulation of IL-1? action(6).

IL-1? is produced primarily by monocytes and macrophages (7) but also by astrocytes, oligodendroglia, adrenal cortical cells, NK cells, endothelial cells, keratinocytes, megakaryocytes, platelets, neurons, neutrophils, osteoblasts, Schwann cells, trophoblasts, T cells, and fibroblasts. IL-1 has multiple immunological functions including enhancement of IL-2 production by T cells and activation of B-cells (BAF) and thymocytes(8-10). A true pleiotrope, IL-1 may have tumoricidal activity via its release of IL-2 and Interferon gamma and indirectly antiviral by stimulating to release interferon beta(11).

Low levels of IL-1? have been reported in normal serum(12). It is thought that IL-1 genes are induced to respond to tissue damage or in infection. Elevated levels have been reported in a number of infectious disease conditions and in noninfectious inflammatory conditions such as Crohn

Gery L.,et al.(1972). J Exp Med 136, 128.

March CJ., et al.(1985). Nature 315,641.

Gray PW., et al.(1986). J Immunol 137, 3644.

Dinarello CA.(1989). Adv Immunol 44,153.

Hannum CH., et al.(1990). Nature 343,336.

Eisenberg SP., et al.(1990). Nature 343,341.

Wewers, M.D. et al. (1997) J. Immunol. 159:5964.

Oppenheim JJ., et al.(1986).Immunol Today7,45.

Dinarello CA., et al.(1986). J Clin Invest77,1734.

FalkoffRJ., et al.(1984). J Immunol 133,692.

Ben-Aribia MH., et al.(1987). J Immunol139,443.

Gahring LC.(1984). Fed Proc 43,462.

Eastgate JA., et al.(1988).Lancet2,706.

Bodel PT.,et al.(1986).Br J Exp Pathol 49,11.